Eyebright Medical Technology (Beijing) Co., Ltd. (SHA:688050)

China · Delayed Price · Currency is CNY

39.22

-1.26 (-3.11%)

Aug 24, 2026, 3:00 PM CST

SHA:688050 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,524	1,483	1,410	951.18	579.5	433.07
Revenue Growth	4.60%	5.16%	48.24%	64.14%	33.81%	58.61%
Gross Profit	940.25	926.15	930.19	721.14	491.15	364.99
Operating Income	362.43	364.93	437.5	308.16	231.62	157.89
Net Income	264.89	268.17	388.4	303.98	232.69	171.34
Earnings Per Share	1.37	1.40	2.05	1.60	1.23	0.91
EPS Growth	-31.31%	-31.71%	28.13%	30.31%	35.58%	50.93%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
China	1,377
Overseas	105.48
Total	1,483

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	728.83	796.14	496.17	556.78	836.86	953.35
Total Debt	1,299	601.5	608.9	419.23	162.79	154.85
Net Cash (Debt)	-570.1	194.64	-112.73	137.55	674.07	798.5
Net Cash Growth	-	-	-	-79.59%	-15.58%	-19.11%
Net Cash Per Share	-2.96	1.02	-0.60	0.72	3.56	4.22

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	312.35	369.15	347.75	212.62	250.13	219.3
Capital Expenditures	-97.96	-123.14	-329.48	-370.34	-271.03	-311.22
Free Cash Flow	214.39	246.01	18.27	-157.72	-20.9	-91.92
Free Cash Flow Growth	95.86%	1246.45%	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	61.71%	62.46%	65.97%	75.82%	84.75%	84.28%
Operating Margin	23.79%	24.61%	31.03%	32.40%	39.97%	36.46%
Pretax Margin	18.82%	19.51%	30.57%	34.45%	45.57%	43.36%
Profit Margin	17.38%	18.09%	27.55%	31.96%	40.15%	39.56%
FCF Margin	14.07%	16.59%	1.30%	-16.58%	-3.61%	-21.22%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 24, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.320	0.320	0.350	0.272	0.283	0.206
Dividend Per Share Growth	-8.57%	-8.57%	28.58%	-3.92%	37.79%	32.13%
Dividend Yield	0.77%	0.53%	0.39%	0.29%	0.22%	0.18%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 24, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	28.55	43.75	44.42	59.57	104.27	129.00
Forward PE	20.32	26.56	29.85	46.16	81.03	105.28
P/FCF Ratio	35.39	47.69	944.35	-	-	-
PS Ratio	4.98	7.91	12.24	19.04	41.87	51.04